Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients
- 4 August 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 112 (5) , 884-889
- https://doi.org/10.1002/ijc.20491
Abstract
Although multiple myeloma (MM) is predominantly a disease of the elderly, few studies have focused on the identification of prognostic factors in this group of patients. Four hundred twenty five MM patients >65 years were uniformly treated with chemotherapy (MP or VCMP/VBAD). Multivariate analysis identified 4 factors with independent unfavorable prognostic influence: high percentage of S-phase bone marrow plasma cells (>2.5%); elevated beta(2) microglobulin (B2M) (>4 mg/L); age >80 years old; and LDH serum levels (above normal limit). The S-phase value was the most powerful independent prognostic factor to discriminate subgroups of patients with different prognosis. Thus, 3 main risk categories could be identified according to S-phase values: 3%, with median survivals of 34, 22 and 12 months, respectively (p < 0.0001). Our study also proved the value for elderly patients of the recently developed International Score System (ISS) based on B2M and albumin. Furthermore, the number of S-phase cells helped to subdivide the ISS III Group identifying a subset of patients with very poor prognosis defined by an additional high S-phase, who displayed a median survival of only 8 months. These results demonstrate that elderly patients can be accurately classified according to prognosis, which may be particularly valuable when comparing the efficacy of new treatment strategies. Moreover, our results underline the high prognostic value of proliferative activity of PC, a parameter that should be considered in routine laboratory investigations of MM.Keywords
Funding Information
- Direccion General de Enseñanza Superior (PM97-0161)
- Red Española de Mieloma (G03/136)
- M.M. Jevit S.A. Firm
- FIS-SS (PI-02/0905)
- Fundación Lair (30601)
This publication has 35 references indexed in Scilit:
- Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patientsBone Marrow Transplantation, 2003
- Multiple myeloma: evolving genetic events and host interactionsNature Reviews Cancer, 2002
- Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myelomaBritish Journal of Haematology, 2001
- Multiple myeloma in elderly patients: presenting features and outcomeEuropean Journal of Haematology, 2001
- Age Is Not a Prognostic Variable With Autotransplants for Multiple MyelomaBlood, 1999
- Presenting Features and Prognosis in 72 Patients With Multiple Myeloma Who Were Younger Than 40 YearsBritish Journal of Haematology, 1996
- 3Immunophenotype and DNA cell content in multiple myelomaBailliere's Clinical Haematology, 1995
- A new staging system for multiple myeloma based on the number of S- phase plasma cellsBlood, 1995
- A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patientsBlood, 1980
- Multiple Myeloma in Young PersonsAnnals of Internal Medicine, 1976